Fasudil is under clinical development by Woolsey Pharmaceuticals and currently in Phase II for Amyotrophic Lateral Sclerosis. According to GlobalData, Phase II drugs for Amyotrophic Lateral Sclerosis have a 65% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Fasudil’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Fasudil overview
Fasudil (Eril) is a vasodilator agent. It was formulated as injectable solution and powder for solution for intravenous route of administration. Eril is indicated for the improvement of cerebral ischemic symptoms accompanying the cerebral vasospasm and its subarachnoid hemorrhage surgery.
AT-877 (fasudil) is under development for the treatment of amyotropic lateral sclerosis, frontemporal dementia, progressive supranuclear palsy, corticobasal degeneration and Huntington's disease. It was also under development for pulmonary arterial hypertension, acute cerebral infarction, angina pectoris, atherosclerosis and spinal cord injury.
Woolsey Pharmaceuticals overview
Woolsey Pharmaceuticals specializes in reinventing ways to treat some of the world’s most challenging diseases. The company is headquartered in New York City, New York, the US
For a complete picture of Fasudil’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
